

14 January 2021

Omni Innovation Enters Licencing Agreement

Key Territories of Australia, China and Europe Licenced

- **Omni Innovation (38% owned by EVE) has entered into a Binding Term Sheet with Myopharm Limited for rights to Omni Innovation's clinically proven pre-meal glycaemic control product for Type 2 diabetes and Pre-Type 2 diabetes**
- **Agreement provides Myopharm with an exclusive licence for the key territories of Australia, China and UK/Europe**
- **Omni Innovation free to develop other licencing / distribution arrangements in other territories including large markets of USA and India**

EVE Investments (ASX:EVE, EVE or the Company), a vertically integrated health, nutrition and wellness company, provides an update on licencing activities at Omni Innovation, a medical technology company focused on medical nutrition which is 38% owned by EVE.

Omni Innovation ("Omni") has entered into a binding Term Sheet agreement with Myopharm Limited ("Myopharm"), an unlisted Australian biotechnology company that has intellectual property assets for the novel development of improving muscle growth and human therapeutic purposes.

As part of this agreement, Myopharm will be granted a 15-year licence for the manufacture, marketing and distribution of Omni's foundation product, the clinically proven pre-meal glycaemic control product for Type 2 diabetes and Pre-Type 2 diabetes, throughout Australia, mainland China and the UK/Europe. The licence is exclusive, subject to meeting minimum annual royalty payments to Omni.

Myopharm will position the product to be sold through a prescription channel in Australia and Europe, an approach not explored by previous licence holders in those markets. The product is expected to be launched through Myopharm in Australia in 2021 with the other territories to follow. Myopharm intends to complete an IPO during 2021 on the ASX.

Omni is free to pursue licencing arrangements in other territories including the USA and India, both territories with large populations of those living with diabetes and pre-diabetes as well as being markets that Omni has patented its pre-meal drink technology.

Agreement terms

This agreement includes a mixture of upfront and deferred licencing fees as well as an on-going royalty on product sales. Initial upfront consideration of \$70,000 has already been received as well as \$265,000 in equity.

Further cash payments of the initial licence fees of \$565,000 are due in various instalments up to 31 January 2024.

On-going royalties equal to 5% of wholesale sales are payable up until 31 December 2027 and thereafter at a rate of 3%, payable to Omni each quarter.

For personal use only

Terms and conditions of the term sheet are binding, and a final licencing agreement is to be completed within 45 days. If not completed, the term sheet remains the binding document for the licencing agreement.

Commenting on the licencing agreement, Managing Director Bill Fry said: “The new licencing agreement for Omni Innovation’s pre-meal drink is very encouraging. We are excited to see Myopharm take on the licence in these territories and roll out its prescription channel model for this unique, scientifically validated product.”

Authorised for release by Bill Fry, Managing Director.

— ENDS —

For more information, please contact:

Company enquiries

Bill Fry, Managing Director

Eve Investments Ltd

+61 8 6465 5500

billf@eveinvestments.com.au

Media enquiries

Melissa Hamilton

Media and Capital Partners

P: +61 417 750 274

melissa.hamilton@mcpartners.com.au

About EVE Investments

EVE Investments (ASX: EVE) is a leading, vertically integrated producer of branded nutrition, health and wellness products. The Company has global reach and application to fast-growing markets across Australia and New Zealand, Asia Pacific and North America. Our mission is to help provide access to the world’s best natural organic products that have demonstrated medicinal benefits and can help enrich the lives of everyday people.

For further information, please visit www.eveinvestments.com.au and follow us on Twitter @EVEInvestments

For personal use only